Alumis falls -16.1%

Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS

Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James

Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says

Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating

Alumis Inc. : Oppenheimer Raises Target Price to $55 From $50

Alumis price target raised to $55 from $50 at Oppenheimer

Alumis Is Maintained at Buy by HC Wainwright & Co.

Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission

Alumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials

U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan

Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib

Alumis says Phase 3 trials show envudeucitinib boosts psoriasis skin clearance by Week 24

Alumis: New Data From Its Phase 3 Onward1 & Onward2 Clinical Trials Evaluating Envudeucitinib

Alumis: Envudeucitinib Showed Favorable Safety & Tolerability Profile Consistent With Phase 2 Program, No New Safety Signals Observed

Alumis: Envudeucitinib Showed Robust Skin‑Clearance, Achieving High Thresholds of Clinical Responses From Week 16 to Week 24 in Both Trials

Alumis: Continues to Evaluate Long-Term Efficacy & Safety of Envudeucitinib in Onward3 Long-Term Extension Trial